Regeneron extends research agreement with Decibel Therapeutics

By The Science Advisory Board staff writers

November 22, 2021 -- Regeneron has extended its research agreement with Decibel Therapeutics for the development of gene therapies for hearing loss.

The agreement will be extended through November 2023, and Regeneron will pay Decibel and extension fee of $10 million in the fourth quarter of 2022.

The collaboration was initially launched in 2017. Under the agreement, Decibel is developing three gene therapies that target congenital, monogenic hearing loss with Regeneron. In 2022, Decibel plans to begin a phase I/II clinical trial of DB-OTO, its lead gene therapy candidate, the two firms said.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here